Targeted therapies: Focus on a new strategy for gastrointestinal tumors

Critical Reviews in Oncology/Hematology

Volumn 47, Issue 3, 2003, Pages 261-271

  Nicolella, D ^a   Maione, P ^a   Gridelli, C ^a  

^a S G MOSCATI HOSPITAL   (Italy)

Author keywords

Angiogenesis inhibitors; COX 2 inhibitors; EGFR inhibitors; Gastrointestinal tumors; Targeted therapies

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CELECOXIB; CETUXIMAB; CGP 69846A; CYCLOOXYGENASE 2 INHIBITOR; EDRECOLOMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; IMATINIB; IRINOTECAN; ISIS 2503; LONAFARNIB; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; THALIDOMIDE; TIPIFARNIB; TRASTUZUMAB; VANDETANIB; VASCULOTROPIN ANTIBODY;

ABDOMINAL PAIN; ACNE; ALLERGIC REACTION; ANEMIA; ANKLE EDEMA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG TOLERABILITY; EDEMA; FATIGUE; FOLLICULITIS; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GASTROINTESTINAL TUMOR; HUMAN; LIVER METASTASIS; MALAISE; NAUSEA; NEUTROPENIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; POLYARTHRITIS; RASH; REVIEW; SIGNAL TRANSDUCTION; SKIN TOXICITY;

EID: 0042787020     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(03)00057-X     Document Type: Review

References (70)

1. Calabresi P., Parks R.E. Chemotherapy of neoplastic disease. Goodman and Gilman's, the pharmacological basis of therapeutics. 6th ed. 1980;1249-1313.
2. Oliff A., Gibbs J.B., McCormick F. New molecular targets for cancer therapy. Sci. Am. 275:1996;144-149.
3. Boral A.L., Dessain S., Chabner B.A. Clinical evaluation of biological targeted drugs: obstacles and opportunities (review). Cancer Chemother. Pharmacol. 42:(Suppl):1998;S3-S21.
4. Gelmon K.A., Eisenhauer E.A., Harris A.L., Ratain M.J., Workman P. Anticancer agents targeting signalling molecules and cancer cell environment: challenges for drug development? J. Natl. Cancer Inst. 91:1999;1281-1287.
5. Dy G.K., Haluska P., Adjei A.A. Novel pharmacological agents in clinical developments for solid tumors. Expert Opin. Invest. Drugs. 10:(12):2001; 2059-2088.
6. Price P. Changes in 18F-FDG uptake measured by PET as a pharmacodynamic end-point in anticancer therapy. How far we got? Br. J. Cancer. 83:2000;281-283.
7. Klapper L.N., Kirschbaum M.H., Sela M., Yarden Y. Biochemical and clinical implications of the ErbB/HER signalling network of growth factor receptors. Adv. Cancer Res. 77:2000;25-79.
8. Kawamoto T., Mendelsohn J., Le A., Sato G.H., Lazar C.S., Gill G.N. Relation of epidermal growth factor receptor concentration to growth of human epidermoid carcinoma A431 cells. J. Biol. Chem. 259:1984;7761-7766.
9. Saeki T., Salomon D.S., Johnson G.R., et al. Association of epidermal growth factor-related peptides and type I receptors with prognosis of human colorectal carcinomas. Jpn J. Clin. Oncol. 25:(6):1995;240-249.
10. Baselga J. The EGFR as a target for anticancer therapy-focus on cetuximab. Eur. J. Cancer. 37:(Suppl 4):2001;16-22.
11. Saltz L., Meropol N.J., Loehrer P.J., Waskal H., Needle M.N., et al. Single agent IMC-C225 (Erbitux) has activity in CPT-11 refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR). Proc. Am. Soc. Clin. Oncol. 21:2002;504.
12. Folprecht G., Haag C., Beutel G., et al. Cetuximab in combination with irinotecan, infusional 5FU and folinic acid is a safe and active regimen in metastatic colorectal cancer expressing epidermal growth factor receptor (EGFR). Tumori. 1:(2):2002;S82.
13. Saltz L., Rubin M., Hochster H., et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer that expresses epidermal growth factor receptor (EGFR). Proc. Am. Soc. Clin. Oncol. 20:2001;7.
14. Rosenberg A.H., Loehrer P.J., Needle M.N., et al. Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer that expresses the epidermal growth factor receptor. Proc. Am. Soc. Clin. Oncol. 21:2002;536.
15. Schoffski P., Lutz M.P., Folprecht G., et al. Cetuximab (C225) plus irinotecan (CPT-11) plus infusional 5FU-folinic acid (FA) is safe and active in metastatic colorectal cancer, that expresses epidermal growth factor receptor (EGFR). Proc. Am. Soc. Clin. Oncol. 21:2002;633.
16. Cobleigh M.A., Vogel C.L., Tripathy D., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2 overexpression metastatic breast cancer that as progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17:1999;2639-2648.
17. Hwang J.J., Sinicrope F., Safran H., et al. A phase II trial of irinotecan and trastuzumab (Herceptin) in patients overexpressing HER-2/neu in metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 20:2001;565.
18. Alberti S. Trop molecules as targets for anti-tumor immunotherapy in man. Tumori. 87:(6):2001;S4-S7.
19. Riethmuller G., Holz E., Schlimok G., et al. Monoclonal antibody therapy for resected Dukes C colorectal cancer: seven year outcome of a multicenter randomised trial. J. Clin. Oncol. 16:1998;1788-1794.
20. Punt C.J.A., Nagy A., Douillard J.Y., et al. Edrecolomab (17-1A antibody) alone or in combination with 5 fluorouracil based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a phase III study. Proc. Am. Soc. Clin. Oncol. 20:2001;487.
21. Fields A.L., Keller A.M., Schwartzberg, et al. Edrecolomab (17-1A antibody) (EDR) in combination with 5-fluorouracil (FU) based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a randomised north American phase III study. Proc. Am. Soc. Clin. Oncol. 21:2002;508.
22. Ciardiello F., Caputo R., Bianco R., et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin. Cancer Res. 7:(5):2001;1459-1465.
23. Kris M.G. ZD1839 (IRESSA) activity and safety in non small cell lung cancer patients validate preclinical data. Lung Cancer. 29:(140):2000;233. Abstract.
24. Sirotnak F.M., Zakowski M.F., Miller V.A., Scher H.I., Kris M.G. Efficacy of cytotoxics agents against human tumor xenografts is markedly enhanced by co-administration of ZD1839 (Iressa), an inhibitor of tyrosine kinase. Clin. Cancer Res. 6:2000;4885-4892.
25. Braun A., Schleucher N., Dirsch O., et al. Combination therapy with the epidermal growth factor receptor inhibitor ZD1839 (Iressa) and irinotecan in human colon cancer cells. A preclinical evaluation. Tumori. 1:(2):2002;S93.
26. Hammond L.A., Figueroa J., Scwartzberg L. Feasibility and pharmacokinetic trial of ZD1839 (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in combination with 5-fluorouracil and leucovorin in patients with advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol. 20:2001;544.
27. Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344:2001;1038-1042.
28. Demetri G.D. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. Semin. Oncol. 28:(5 Suppl 17):2001;19-26.
29. Casali P, Verweij J, Zalcberg J, et al. Imatinib (Glivec) 400 vs in patients with gastrointestinal stromal tumors (GIST): a randomised phase III trial from the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group (ISG) and the Australasian Gastro-Intestinal Trials Group (AGITG). A toxicity report. Proc. Am. Soc. Clin. Oncol. 2002; 21: 1650.
30. Rowinsky E.K., Windle J.J., Von Hoff D. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J. Clin. Oncol. 17:1999;3631-3652.
31. Bos J.L. Ras oncogenes in human cancer: a review. Cancer Res. 49:1989;4682-4689.
32. Adjej A.A., Erlichmman C., Davis J.N., et al. A phase I trial of the farnesyl transferase inhibitor SCH 66336: evidence for biological and clinical activity. Cancer Res. 60:2000;1871-1877.
33. Lersch C., van Cutsem E., Amado R., et al. Randomized phase II study of SCH 66336 and gemcitabine in the treatment of metastatic adenocarcinoma of the pancreas. Proc. Am. Soc. Clin. Oncol. 20:2001;608.
34. End D.W., Smets G., Todd A.V., et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 61:(1):2001;131.
35. Zujewsky J., Horak I.D., Bol C.J., et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J. Clin. Oncol. 18:2000;927-941.
36. Cohen S.J., Ho L., Ranganathan S., et al. Phase II and pharmacodynamic trial of the farnesyl transferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic carcinoma. Proc. Am. Soc. Clin. Oncol. 21:2001;545.
37. Macdonald J.S., Chansky K., Whitehead R., et al. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer. A Southwest Oncology Group (SWOG) Study. Proc. Am. Soc. Clin. Oncol. 21:2002;548.
38. Van Cutsem E., Karasek P., Oettle H., et al. Phase III trial comparing gemcitabine+R115777 (Zarnestra) versus gemcitabine+placebo in advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol. 21:2002;517.
39. Cunningham D., De Gramont A., Scheithauer W., et al. Randomized double-blind placebo-controlled trial of the farnesyltransferase inhibitor R115777 (Zarnestra) in advanced refractory colorectal cancer. Proc. Am. Soc. Clin. Oncol. 21:2002;502.
40. Fox S.B., Gasparini G., Harris A.L. Angiogenesis: pathological, prognostic and growth factor pathways and their link to trial design and anticancer drugs. Lancet Oncol. 2:2001;278-289.
41. Folkman J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82:1990;4-6.
42. Ciardiello F., Damiano V., Bianco R., et al. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J. Natl. Cancer Inst. 88:1996;1770-1776.
43. Folkman J. Antiangiogenic gene therapy. Proc. Natl. Acad. Sci. USA. 95:1998;9064-9066.
44. Albini A., Noonan D., Santi L. Angiogenesis at the interface between basic and clinical research. Int. J. Biol. Markers. 14:1999;202-206.
45. Cascinu S., Staccioli M.P., Gasparini G., et al. Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin. Cancer Res. 6:(7):2000;2803-2807.
46. Cascinu S., Graziano F., Catalano V., et al. Vascular endothelial growth factor (VEGF), p53 and BAX expression in node positive rectal cancer. Relationships with tumor recurrence after adjuvant chemoradiation. Proc. Am. Soc. Clin. Oncol. 20:2001;595.
47. Langmuir V.K., Cobleigh M.A., Herbst R.S., et al. Successful long-term therapy with bevacizumab (Avastin) in solid tumors. Proc. Am. Soc. Clin. Oncol. 21:2002;32.
48. Bergsland E.K., Fehrenbacher L., Novotny W., et al. Bevacizumab (BV)+chemotherapy (CT) may improve survival in metastatic colorectal cancer subjects with unfavourable prognostic indicators. Proc. Am. Soc. Clin. Oncol. 20:2001;2247.
49. Posey J., Ng T., Yang B., et al. A phase I trial of an anti-KDR (VEGFR) chimeric antibody in patient with liver metastases in colorectal cancer (CRC). Proc. Am. Soc. Clin. Oncol. 21:2002;63.
50. Thomas D.A., Kantarjian H.M. Current role of thalidomide in cancer treatment. Curr. Opin. Oncol. 12:(6):2000;564-573.
51. Eisen T. Thalidomide in solid malignancies. J. Clin. Oncol. 20:(11):2002;2607-2609.
52. Govindarajan R., Maddox A.M., Safar A.M., et al. The efficacy of thalidomide and irinotecan in metastatic colorectal carcinoma (phase II study). Proc. Am. Soc. Clin. Oncol. 21:2002;2222.
53. Merin J.M., Lee F.C. Palliative benefit for salvage treatment with capecitabine and thalidomide for gastric and/or esophageal adenocarcinoma: a retrospective case series. Proc. Am. Soc. Clin. Oncol. 21:2002;2391.
54. Schwartz J.D., Sung M.W., Lehrer D., et al. Thalidomide for unresectable hepatocellular cancer (HCC) with optional interferon-alpha upon disease progression. Proc. Am. Soc. Clin. Oncol. 21:2002;1847.
55. Xu Y., Ellison C., Martin E., et al. A phase II study of thalidomide in metastatic neuroendocrin tumors. Proc. Am. Soc. Clin. Oncol. 21:2002;1931.
56. Belotti D., Paganoni P., Giavazzi R. MMP inhibitors: experimental and clinical studies. Int. J. Biol. Markers. 14:1999;232-238.
57. Woitowicz-Praga S.M., Dickson R.B., Hawkins M.J. Matrix metalloproteinase inhibitors. Invest. New Drugs. 15:1997;61-75.
58. Rosemurgy A., Harris J., Langleben A., Casper E., Goode S., Rasmussen H. Marimastat in patients with advanced pancreatic cancer: a dose-finding study. Ann. J. Clin. Oncol. 22:(3):1999;247-252.
59. Evans J.D., Stark A., Johnson C.D., et al. A phase II trial of marimastat in advanced pancreatic cancer. Br. J. Cancer. 85:(12):2001;1865-1870.
60. Iannitti D., McKenna M., Pacha C.M., et al. Marimastat following chemoradiation for locally advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol. 21:2002;2285.
61. Bramhall S.R., Schulz J., Nemunaitis J., Brown P.D., Baillet M., Buckels J.A. A double blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br. J. Cancer. 87:(2):2002;161-167.
62. King J., Clingan P., Morris D.L. Placebo control double-blind randomised clinical trial of the matrix metalloproteinase inhibitor marimastat in patients with inoperable colorectal cancer liver metastases: significant survival advantage in patients with musculo skeletal symptoms. Proc. Am. Soc. Clin. Oncol. 21:2002;537.
63. Bramhall S.R., Hallissey M.T., Whiting J., et al. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br. J. Cancer. 86:(12):2002;1864-1870.
64. Dempke W., Rie C., Grothey A., Schmoll H.J. Cycloxygenase-2: a novel target for cancer chemotherapy? J. Cancer Res. Clin. Oncol. 127:(7):2001; 411-417.
65. Robles C., Ying D., Xu R., et al. Cycloxygenase-2 (COX-2) expression and human colon cancer. Proc. Am. Soc. Clin. Oncol. 20:2001;2164.
66. Blanke C.D., Benson A.B. III, Dragovich T., et al. A phase II trial of celecoxib, irinotecan, 5-fluorouracil and leucovorin in patients with unresectable or metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 21:2002;505.
67. Lengauer C., Kinzler K.W., Vogelstein B. Genetic instability in human cancers. Nature. 396:(6712):1998;643-649.
68. Ghimenti C., Tannegard P., Walburg S., et al. Microsatellite instability and mismatch repair gene inactivation in sporadic pancreatic and colon tumors. Br. J. Cancer. 80:(1-2):1999;11-16.
69. Knight R.D., Miller R.R., Pirotta N., et al. Firstline irinotecan (C), fluorouracil (F), leucovorin (L) especially improves survival (OS) in metastatic coilorectal cancer (MCRC) patients (PT) with favourable prognostic indicators. Proc. Am. Soc. Clin. Oncol. 19:2000;991.
70. Aschele C., Lonardi S., Monfardini S. Thymidylate synthase expression as a predictor of clinical response to fluoro pyrimidinebased chemotherapy. Cancer Treat. Rev. 28:2002;2747.